Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquir
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2
New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchas
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Su
Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA? NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ:
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
09:00am, Thursday, 26'th Mar 2026
LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aquestive Therapeutics, Inc., (“Aquestive” or the "Company") (NASDAQ: AQST) investors off a class action on behalf of
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDA
New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options
Wall Street Reassessment: Analyst Opinion Evolution on AQST NEW YORK, March 25, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST)
New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQS
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is
NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
